CLINICAL SIGNIFICANCE OF RESISTIN IN DEMENTIA WITH EATING DISORDERS

TAMAR LAZASHVILI; VERA KAPETIVADZE; TEIMURAZ SILAGADZE; REVAZ TABUKASHVILI; ZVIAD MAGLAPHERIDZE; IRINA KAPETIVADZE

doi:10.52340/jecm.2023.06.12

CLINICAL SIGNIFICANCE OF RESISTIN IN DEMENTIA WITH EATING DISORDERS

Authors

TAMAR LAZASHVILI Tbilisi State Medical University
VERA KAPETIVADZE Tbilisi State Medical University
TEIMURAZ SILAGADZE Tbilisi State Medical University
REVAZ TABUKASHVILI Tbilisi State Medical University
ZVIAD MAGLAPHERIDZE Tbilisi State Medical University
IRINA KAPETIVADZE Tbilisi State Medical University

DOI:

https://doi.org/10.52340/jecm.2023.06.12

Keywords:

Dementia, Eating disorders, dysphagia, resistin

Abstract

SUMMARY

Purpose: The main goal of our study was to study the Clinical significance of resistin in patients with ongoing dementia with eating disorders.

Methods: 77 patients with dementia were studied. The average age of the research group was 78.0 ± 11.1 years. Dementia patients were divided into three groups: Group 1 - without eating disorders - n=19 (24.7%); Group 2 - eating disorders without dysphagia - n=28 (36.4%); Group 3 - eating disorders with dysphagia - n=30 (39.0%). The control group was made up of 22 people of the same age group who did not report dementia and/or eating disorders before participating in the study (average age - 73.8 ± 28.3 years). The degree of dementia was assessed by the MMSE, CDR and FAST scales. The presence of eating disorders was diagnosed with EdFED-Q and MNA-SF questionnaires. Eating disorders were observed in 58 patients (75.3%), and dysphagia in 30 (39.0%).

Results: the results of the study showed that according to the MNA-SF scale, eating disorders in group 3 are more severe than in groups 1 and 2 (p<0.001, in both cases), and in group 2 - than in group 1 (p=0.003). The MMSE score in the dementia with dysphagia group is significantly lower than the other two groups. The mean MMSE score of patients without dysphagia but with eating disorders is significantly lower than the mean MMSE score of patients without eating disorders: In case of CDR questionnaire, dysphagia in dementia group compared to other 2 groups (p<0.001). CDR indicators of group 1 and group 2 did not differ from each other (p=0.100, NS).

Conclusion: Eating disorders have a large and reliable impact on both the course of dementia and the metabolic characteristics of individuals with dementia. Among these disorders, a special place is occupied by dysphagia, which reliably worsens the degree of dementia and the levels of metabolites.

Downloads

Download data is not yet available.

References

გაბუნია თ. ქაროსანიძე ი. კუჭავა დ. კილაძე უ. ბოკუჩავა მ. ჭყონია ე. დემენციის გამოვლენა და მართვა ზოგად საექიმო პრაქტიკაში, 2010 წ, გვ 4-8.

ბერია ზ. ნანეიშვილი გ. ფსიქიატრია, 2017 წ. გვ 74-76.

Bohan N.A. V.Ya. Semke; Comorbidity in narcology: a scientific publication, Research Institute of Mental Health, TSC, Tomsk University Press, 2009. 510 P.

გელდერი მ. ჰარისონი პ. ქოუენი ფ. ოქსფორდის მოკლე სახელმძღვანელო ფსიქიატრიაში. 2012 წ.

Prince M, Wimo A, Guerchet M, World Alzheimer report 2015: The global impact of dementia. An analysis of prevalence, Alzheimer's Disease International (ADI). 2015

World Health Organization Neurological Disorders: Public Health Challenges. – Switerland: World Health Organization, 2006. C. 204 – 207

Piguet O, Petersén A, Yin Ka Lam B, Eating and hypothalamus changes in behavioral-variant frontotemporal dementia, Annals of Neurology 2011. Vol. P. 312–319.

Zhao Q.F, Tan L, Wang H.F, The prevalence of neuropsychiatric symptoms in Alzheimer's disease, Journal of Affective Disorders. 2016; 190:264-271.

Cole D, Optimising nutrition for older people with dementia – Nurs Stand. 2012. Jan;26(20):41–48.

Fostinelli S, De Amicis R, Leone A, Giustizieri V, Binetti G, Bertoli S, Battezzati A, Cappa SF. Eating Behavior in Aging and Dementia: The Need for a Comprehensive Assessment. Front Nutr. 2020; 7:604488. doi: 10.3389/fnut.2020.604488.

Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288:1475–83. 10.1001/jama.288.12.1475.

Petersson SD, Philippou E. Mediterranean diet, cognitive function, and dementia: a systematic review of the evidence. Adv Nutr. 2016;7:889–904. 10.3945/an.116.012138.

Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol.2018;14:653–66. 10.1038/s41582-018-0070-3.

Lehtisalo J, Levälahti E, Lindström J, Hänninen T, Paajanen T, Peltonen M, et al. Dietary changes and cognition over 2 years within a multidomain intervention trial-the finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER). Alzheimers Dement. 2019;15:410–7. 10.1016/j.jalz.2018.10.001.

Marijn Stok F, Renner B, Allan J, Boeing H, Ensenauer R, Issanchou S, et al. dietary behavior: an interdisciplinary conceptual analysis and taxonomy. Front Psychol. 2018;9:1689. 10.3389/fpsyg.2018.01689.

LaCaille L. Eating behavior. In: Gellman MD, Turner JR, editors. Encyclopedia of Behavioral Medicine. New York, NY: Springer New York; 2013. p. 641–642.

Ikeda M, Brown J, Holland AJ, Fukuhara R, Hodges JR. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatr 2002;73:371–6. 10.1136/jnnp.73.4.371.

Soto M, Andrieu S, Gares V, Cesari M, Gillette-Guyonnet S, Cantet C, et al. Living alone with alzheimer's disease and the risk of adverse outcomes: results from the plan de Soin et d'Aide dans la maladie d'Alzheimer study. J Am Geriatr Soc. 2015;63:651–8. 10.1111/jgs.13347.

White H, Pieper C, Schmader K. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc. 1998;46:1223–7. 10.1111/j.1532-5415.1998.tb04537.x.20.

Gillette-Guyonnet S, Nourhashemi F, Andrieu S, de Glisezinski I, Ousset PJ, Riviere D, et al. Weight loss in Alzheimer disease. Am J Clin Nutr. 2000;71:637S-42S. 10.1093/ajcn/71.2.637s.

Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriatr Psychiatry 2005;13:460–8. 10.1097/00019442-200506000-00004.

Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer's disease. Lancet 1997; 349:1546–9. 10.1016/S0140-6736(96)10203-8.

Power DA, Noel J, Collins R, O'Neill D. Circulating leptin levels and weight loss in Alzheimer's disease patients. Dement Geriatr Cogn Disord. 2001;12:167–70. 10.1159/000051252.

Holscher C. Insulin signaling impairment in the brain as a risk factor in Alzheimer's disease. Front Aging Neurosci. 2019;11:88. 10.3389/fnagi.2019.00088.

Hiller AJ, Ishii M. Disorders of body weight, sleep and circadian rhythm as manifestations of hypothalamic dysfunction in Alzheimer's disease. Front Cell Neurosci. 2018;12:471. 10.3389/fncel.2018.00471.

Boccardi V, Ruggiero C, Patriti A, Marano L. Diagnostic Assessment and Management of Dysphagia in Patients with Alzheimer's Disease. J Alzheimers Dis. 2016;50(4):947-55. doi: 10.3233/JAD-150931.

Alagiakrishnan K, Bhanji RA, Kurian M. Evaluation and management of oropharyngeal dysphagia in different types of dementia: a systematic review. Arch Gerontol Geriatr. 2013;56(1):1-9. doi: 10.1016/j.archger.2012.04.011.

Y. Malekizadeh, A. Holiday, D. Redfearn, J. Ainge, G. Doherty, J. Harvey, A leptin fragment mirrors the cognitive enhancing and neuroprotective actions of leptin. Cereb. Cortex 2016;27(10):4769–4782.

W. Hu, D. Holtzman, A. Fagan, L. Shaw, et al. Alzheimer’s disease Neuroimaging Initiative, 2012. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer’s disease, Neurology 2012;79:897–905.

S. Walter, M. Letiembre, Y. Liu, et al. Role of the toll-like receptor 4 inneuroinflammation in Alzheimer’s disease. Cell, Physiol. Biochem 2007;20:947–956.

M. Kizilarslanoğlu, O. Kara, Y. Yeşil, et al. Alzheimer disease, inflammation, and novel inflammatory marker: resistin, Turkish J. Med. Sci. 2015;45:1040–1046.

Frisardi V, Solfrizzi V, Seripa D, et al. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer’s disease. Ageing Res Rev 2010;9:399–417.

Parimisetty A, Dorsemans AC, Awada R, Ravanan P, Diotel N, d’Hellencourt CL. Secret talk between adipose tissue and central nervous system via secreted factors-an emerging frontier in the neurodegenerative research. J Neuroinflammation 2016;13:67.

Miralbell J, Lo´pez-Cancio E, Lo´pez-Oloriz J, et al. Cognitive patterns in relation to biomarkers of cerebrovascular disease and vascular risk factors. Cerebrovasc Dis 2013;36:98–105.

Bednarska-Makaruk M, Graban A, Wisniewska A, et al. Association of adiponectin, leptin and resistin with inflammatory markers and obesity in dementia. Biogerontology 2017;18:561–580.

Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab 2011;22:259–265.

Olefsky JM, Glass CK Macrophages, inflammation, and insulin resistance. Ann Rev Physiol 2010;72:219–246.

Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ Human resistin stimulates the proinflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005;334:1092–1101.